Search | Clinical Trials Finder

Conditions: Coronary Artery Disease, Atherosclerosis, Heart Attack
Interventions: Statin, Aspirin tablet, Nexlizet, LEQVIO, Vascepa, Jardiance, Colchicine; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Malignant Neoplasm
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Atorvastatin Calcium, Peripheral Blood Stem Cell Transplantation; Procedure · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Stanford, California • Denver, Colorado • Seattle, Washington

Conditions: Hyperlipidemia, Dyslipidemia
Interventions: Minute Maid Heart Wise orange juice, Welchol; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Dyslipidemias
Interventions: LY3202328, Placebo, Atorvastatin, Simvastatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Miami, Florida • Lenexa, Kansas • Marlton, New Jersey + 1 more

Conditions: Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions: Simvastatin, Doxorubicin/cyclophosphamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Crohn's Ileocolitis, Crohn Disease
Interventions: Rosuvastatin, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Peripheral Arterial Disease
Interventions: Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA); Drug · Behavioral · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 40 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiovascular Disease, Cardiomyopathy, Heart Disease, Myocardial Disease, Myocardial Ischemia
Interventions: Atorvastatin Calcium; Drug
Lead sponsor: Philip Binkley; Other
Eligibility: 18 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and stable statin therapy, Stable statin therapy; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 86
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 83 more

Conditions: High Cholesterol
Interventions: Policosanol, Placebo, Policosanol Plus Already In Use Statin Therapy; Drug · Other
Lead sponsor: James Backes, PharmD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions: Atorvastatin and Lisinopril, Placebo; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: San Diego, California • Bethesda, Maryland

Conditions: Hypercholesterolemia, LDL Cholesterol
Interventions: LGT209 50 mg, LGT209 300 mg, Placebo, Statins (atorvastatin or simvastatin); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Fort Myers, Florida • Miramar, Florida

Conditions: Hyperlipidemia, Coronary Artery Disease
Interventions: Pharmacist Intervention in lipid therapy; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Concord, North Carolina

Conditions: Lupus Erythematosus, Systemic
Interventions: Atorvastatin, Placebo atorvastatin; Drug
Lead sponsor: Laura Schanberg; Other
Eligibility: 10 Years to 21 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Volunteers
Interventions: Atorvastatin, ALG-055009, Rosuvastatin; Drug
Lead sponsor: Aligos Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypertriglyceridemia, Cardiovascular Disease
Interventions: Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 89
States / cities: Muscle Shoals, Alabama • Chandler, Arizona • Phoenix, Arizona + 78 more

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions: Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo, Ezetimibe placebo; Drug · Other
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 16
States / cities: Los Angeles, California • Northridge, California • Ocala, Florida + 13 more

Conditions: Prostate Cancer
Interventions: lovastatin; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 3
States / cities: Richmond, Virginia

Conditions: Sudden Sensorineural Hearing Loss
Interventions: Statin, methylprednisolone, dexamethasone, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiovascular Diseases
Interventions: AMR101, Placebo, Statin therapy; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 8,179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 176
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more

Conditions: Transient Ischemic Attack, Stroke
Interventions: Aspirin, Clopidogrel, Simvastatin; Drug
Lead sponsor: University of Calgary; Other
Eligibility: 40 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atherosclerosis
Interventions: Statin therapy, Lifestyle modification; Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 22 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Neurocognitive Dysfunction
Interventions: atorvastatin; Drug
Lead sponsor: Duke University; Other
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

Evaluation of Combination Cholesterol Treatments in Patients With High Cholesterol.

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin

Effect of Statins on Crohn's Disease

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

Statin Therapy for Ischemic and Nonischemic Cardiomyopathy

Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

Effect of Policosanol as Monotherapy and Adjunctive to Statin Therapy

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention

Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)

A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)

[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury

Oral Statins and Protection From Hearing Loss

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)

Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging

Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery